Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro

dc.contributor.author	Bilir, Ayhan
dc.contributor.author	Erguven, Mine
dc.contributor.author	Ermis, Ezgi
dc.contributor.author	Sencan, Mine
dc.contributor.author	Yazihan, Nuray
dc.date.accessioned	2021-12-21T08:46:45Z
dc.date.available	2021-12-21T08:46:45Z
dc.date.issued	2011
dc.identifier.issn	2005-0380
dc.identifier.uri	https://doi.org/10.3802/jgo.2011.22.4.225
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/2087
dc.description.abstract	Objective: The aim of the study was to investigate whether lithium chloride and medroxyprogesterone acetate can potentiate the cytotoxicity of imatinib mesylate in human endometrial cancer in vitro and the effect of midkine in these therapies. Methods: Im
dc.language.iso	English
dc.publisher	Korean Soc Gynecology Oncology & Colposcopy
dc.rights	Green Published, Green Submitted
dc.title	Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro
dc.type	Article
dc.relation.journal	Journal Of Gynecologıc Oncology
dc.identifier.issue	4
dc.identifier.startpage	225
dc.identifier.endpage	232
dc.identifier.volume	22
dc.identifier.doi	10.3802/jgo.2011.22.4.225
dc.relation.issue	4
dc.relation.volume	22

Bu öğenin dosyaları:

Dosyalar	Boyut	Biçim	Göster
Bu öğe ile ilişkili dosya yok.